Enlivex Ltd. ENLV

ENLV Company Overview

Enlivex Ltd. is a clinical-stage biotechnology company focused on developing macrophage reprogramming immunotherapies for inflammatory and infectious diseases. The company operates within the biotechnology and immunotherapy industries and is primarily engaged in research and development activities rather than commercial product sales. Its lead product candidate, Allocetra™, is designed to reprogram macrophages into their homeostatic state in order to address life-threatening immune dysregulation associated with conditions such as sepsis, solid tumors, and complications related to organ dysfunction and hyperinflammation. The company’s revenue profile has historically consisted primarily of research-related grants, financial income, and capital raising activities, as it has not yet commercialized approved therapies.

Enlivex was founded in Israel and became publicly traded on the Nasdaq Capital Market under the ticker ENLV. The company evolved from early-stage immunology research centered on apoptotic-cell-based therapies and expanded its clinical focus into severe inflammatory conditions with high unmet medical need. Its strategic positioning is based on a differentiated immunomodulatory platform intended to regulate macrophage activity broadly rather than targeting a single inflammatory cytokine pathway. Public filings and company disclosures indicate that the company’s development strategy centers on indications where immune overactivation contributes significantly to morbidity and mortality.